4 Results for "

CCR8-expressing cells

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "CCR8-expressing cells" in MCE Product Catalog:

Cat. No.: HY-P991061
CAS No.: 3024486-14-1
Synonyms: CHS-114; SRF-114

Target:  

CCR

Research Areas:  

Cancer

Tagmokitug (CHS-114; SRF-114) is a fully human IgG1 antibody targeting CCR8. Tagmokitug selectively binds to human CCR8 (Kd = 502 pM) and mediates the death of CCR8-expressing cells via antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis. Tagmokitug selectively eliminates intratumoral regulatory T cells, induces tumor growth inhibition, remodels the tumor immune microenvironment, and promotes the differentiation of cytotoxic CD8 + T cell subsets. Tagmokitug can be used for the research of solid tumors .
loading...
    loading...
Cat. No.: HY-P991481

Target:  

CCR

Research Areas:  

Inflammation/Immunology Cancer

S-531011 is a high-affinity, selective, and reversible CCR8 ligand with antibody-dependent cellular cytotoxicity (ADCC) against CCR8-expressing cells. S-531011 induces the death of tumor-infiltrating CCR8 + regulatory T cells while preserving regulatory T cells in peripheral blood, thereby reinvigorating anti-tumor immunity. The combination of S-531011 with anti-PD-1 antibody effectively inhibits tumor growth, and S-531011 can be used for research on advanced solid tumors and various cancers including non-small cell lung cancer, ovarian cancer, colon cancer, breast cancer, and pancreatic ductal adenocarcinoma .
loading...
    loading...
Cat. No.: HY-P991944

Target:  

CCR

Research Areas:  

Cancer

ZL-1218 is a selective humanized IgG1 antibody, targeting CCR8. ZL-1218 induces antibody-dependent cellular cytotoxicity (ADCC), leading to NK cell-mediated depletion of CCR8-expressing regulatory T cells (Tregs). ZL-1218 blocks the binding of the CCR8 ligand CCL1 to CCR8 and reduces Treg recruitment by inhibiting the chemotaxis of CCR8 + cells. ZL-1218 reduces intratumoral Treg levels in a dose-dependent manner. ZL-1218 exerts enhanced antitumor activity when combined with the anti-PD-1 antibody. ZL-1218 can be used for solid tumour research .
loading...
    loading...
Cat. No.: HY-P991782

Target:  

CCR

Research Areas:  

Inflammation/Immunology Cancer

Anti-Mouse CCR8 Antibody (C8Mab-2) is an antibody targeting mouse CCR8. Anti-Mouse CCR8 Antibody (C8Mab-2) induces antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis to eliminate CCR8-expressing cells. Anti-Mouse CCR8 Antibody (C8Mab-2) eliminates regulatory T cells in the tumor microenvironment, increases CD8 + T cell infiltration and inhibits tumor growth. Anti-Mouse CCR8 Antibody (C8Mab-2) recognizes the N-terminal amino acid region 1-33 of mouse CCR8, in which Thr20 serves as the core binding epitope amino acid. Anti-Mouse CCR8 Antibody (C8Mab-2) is applicable to research related to colon cancer, breast cancer and bladder cancer .
loading...
    loading...